Stockscreener 앱 받기
10.14
0.15%
0.015
전일 마감가:
$10.13
열려 있는:
$10.135
하루 거래량:
40,846
Relative Volume:
0.29
시가총액:
$340.23M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.15%
1개월 성능:
+0.64%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.13
$10.15
1주일 범위
$10.12
$10.15
52주 변동 폭
$9.96
$10.27
Drugs Made In America Acquisition Corp Stock (DMAA) Company Profile
명칭
Drugs Made In America Acquisition Corp
전화
954-870-3104
주소
2 PELICAN DR., FORT LAUDERDALE
DMAA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMAA
Drugs Made In America Acquisition Corp
|
10.15 | 339.53M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
7.69 | 1.89B | 2.82B | -191.60M | -407.10M | -0.6794 |
|
AACT
Ares Acquisition Corporation Ii
|
11.51 | 697.78M | 0 | 16.92M | -1.35M | 0.29 |
|
CEP
Cantor Equity Partners Inc
|
40.20 | 516.22M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.45 | 465.78M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.75 | 463.16M | 0 | 1.30M | 0 | 0.0301 |
Drugs Made In America Acquisition Corp 주식(DMAA)의 최신 뉴스
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - TradingView
Layoff Tracker: iTeos Winds Down Operations - BioSpace
Pfizer Inc. - Britannica
Drugs Made In America Faces 10-Q Filing Delay - TipRanks
Financial Snapshot: Analyzing East West Bancorp, Inc (EWBC)’s Key Ratio Metrics - DWinneX
Metric Deep Dive: Understanding Drugs Made In America Acquisition Corp (DMAA) Through its Ratios - DWinneX
Market Resilience: Four Corners Property Trust Inc (FCPT) Finishes Weak at 27.86, Down -1.90 - DWinneX
Daily Progress: Coca-Cola Europacific Partners Plc (CCEP) Drop -0.78, Closing at 88.15 - DWinneX
Financial Analysis: Bio-Key International Inc (BKYI)’s Ratios Unveil Key Insights - DWinneX
Ratio Revelations: Amerant Bancorp Inc (AMTB)’s Financial Metrics in the Spotlight - DWinneX
Closing Strong: Lulus Fashion Lounge Holdings Inc (LVLU) Ends at 0.41, Down -7.73 from Last Close - DWinneX
The top 20 pharma companies by 2024 revenue - Fierce Pharma
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Theratechnologies’ stock soars on disclosure of acquisition offer by U.S. company - Montreal Gazette
After saying overseas drugmakers would have a “big tax to pay,” Trump spares pharmaceuticals from reciprocal tariffs - Sherwood News
'I bought their dream': How a US company's huge land deal in Senegal went bust - Yahoo
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com
Bright Green Unveils Massive $2B Cannabis Strategy with Zero Shareholder Dilution - StockTitan
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - The Manila Times
DRUGS MADE IN AMERICA ACQUISITION CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger - Reuters
7 Best Weight Loss Drug Stocks to Buy in 2025 | Investing | U.S. News - U.S News & World Report Money
Not All Generics Are Created Equal: Study Exposes a 54% Higher Risk in Indian-Made Drugs - SciTechDaily
Brokerages Set TWFG, Inc. (NASDAQ:TWFG) Target Price at $31.86 - Defense World
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly and Company
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Drugs Made in America Acquisition Corp. Forms Advisory Team to Pursue Pharmaceutical Business Acquisitions - Nasdaq
How Vivek Ramaswamy got rich before going into politics - Cincinnati Enquirer
Popular cannabis brand declares Chapter 11 bankruptcy - TheStreet
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod - Fierce Pharma
Drugs Made In America Acquisition Corp. Announces Trading Options for Public Offering Units Starting February 25, 2025 - Nasdaq
Mink Ventures Completes Acquisition of Warren Ni, Cu, Co Patents - The Manila Times
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option - TradingView
Drugs Made In America Acquisition Corp. Secures Additional $30 Million in IPO as Underwriter Fully Exercises Overallotment Option - Nasdaq
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Drugs Made In America Acquisition Corp.’s $200 Million Initial Public Offering - Global Legal Chronicle
Trump wants to put tariffs on prescription drugs. Experts warn it could backfire. - Yahoo Finance
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma - Fierce Pharma
United Parcel Service (UPS) | History, Services, & Facts - Britannica
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential - Fortune
Our History - Baxter
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs - Seeking Alpha
IPO NewsUS IPO Weekly Recap: Active January closes out with several sizable IPOs - renaissancecapital.com
Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering - The Manila Times
Drugs Made In America Acquisition Prices $200 Million IPO - MarketScreener
Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO - SPAC Insider
Top 10 most anticipated drug launches of 2025 - Fierce Pharma
Drugs Made In America Acquisition Corp (DMAA) 재무 분석
Drugs Made In America Acquisition Corp (DMAA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.17%
0.14%
자본화:
|
볼륨(24시간):